Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +2.45K | +6.37% | $0.00 | 40.9K | Sep 30, 2022 | Direct | F1 |
transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +5.32K | +13% | $0.00 | 46.3K | Dec 30, 2022 | Direct | F2 |
transaction | BICX | Common Stock, par value $0.001 | Purchase | $300K | +171K | +370.37% | $1.75 | 218K | Mar 29, 2023 | By Trust | F3 |
transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +2.82K | +1.3% | $0.00 | 220K | Mar 31, 2023 | Direct | F4 |
transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +2.89K | +1.31% | $0.00 | 223K | Jun 30, 2023 | Direct | F5 |
Id | Content |
---|---|
F1 | These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. |
F2 | These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. |
F3 | These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust. |
F4 | These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. |
F5 | These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. |